A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : AEs / adverse events

[Related PubMed/MEDLINE]
Total Number of Papers: 11316
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   AEs  (>> Co-occurring Abbreviation)
Long Form:   adverse events
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2023 A Comprehensive Analysis of COVID-19 Vaccine Discourse by Vaccine Brand on Korean Twitter: Topic and Sentiment Analysis. LDA
2023 A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma. PD-L1, SBRT
2023 A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). GMCs, IgG, OPA, PCV13, PCVs, PD, PD3, PD4
2023 A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. CB, ctDNA, FAK, MEK, OS, PDAC, PFS
2023 A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome. IADL, OS, PFS, SAEs
2023 A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. LSMCFB, NASH
2023 A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis. GCSI-24H, GE, GES
2023 A retrospective analysis of the incidence of severe adverse events among recipients of chiropractic spinal manipulative therapy. SMT
2023 Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis. ARSI, mCRPC, mCSPC, nmCRPC, PRISMA, RCTs, SUCRA
10  2023 Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study. BRAFV600Emut, mCRC
11  2023 Adverse events in neurosurgery: a comprehensive single-center analysis of a prospectively compiled database. CSF
12  2023 Adverse events unlikely after fine-needle aspiration biopsies of thyroid nodules in patients on low-dose aspirin: a prospective controlled systematic single center analysis. FNABs
13  2023 An International Evaluation of a Ceramide-Containing Hydrating Cleanser and Moisturizing Cream for the Improvement of Diabetes Mellitus-Related Xerosis. CER, DM, DSCS, GAIS, QoL
14  2023 Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis. mRNA, ORs
15  2023 Automated Detection of Patient Harm: Implementation and Prospective Evaluation of a Real-Time Broad-Spectrum Surveillance Application in a Hospital With Limited Resources. PPV
16  2023 Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406). BOL, CIV, DOX, OS, PFS, STS
17  2023 Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. CPH, PFS, RCC
18  2023 Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries. CV, EV, FDA, HT, PCa, PRR
19  2023 Categorization of Adverse Events Reported to the FDA Pertaining to Tibia Intramedullary Nailing. FDA, IMN
20  2023 Clinical Value of IL6R Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis. bDMARD, IL-6, IL-6R, RA, SNPs
21  2023 Comparison of endoscopic full-thickness resection and ligation-assisted endoscopic full-thickness resection for small (≤ 1.5 cm) gastric subepithelial tumors originating from muscularis propria. EFTR, SET-MPs
22  2023 Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials. ACR20, MTX, RA, RCTs, SUCRA
23  2023 COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. LNP, saRNA
24  2023 COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5-11 Years Old-Non-Randomized Clinical Trial. allo-HSCT
25  2023 Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study. BCPNN, JAERS, MHRA, PRR, ROR
26  2023 Detection and endoscopic classification of intraductal neoplasms of the bile duct by peroral cholangioscopy with narrow-band imaging (with videos). IN-B, ISL-Bs, NBI, POC, POC-FB
27  2023 Diagnostic outcome and safety of plugged liver biopsy in high-risk patients: a systematic review and meta-analysis. CI, OR, PLB, TJLB
28  2023 Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy. ICI, MEK
29  2023 Effect of arotinolol on chronic heart failure: A systematic review and meta-analysis of randomized controlled trials. BNP, CI, hs-CRP, LVEDD, LVEDV, LVEF, RCTs, SMD, SV
30  2023 Effectiveness of electroacupuncture versus prucalopride for women with severe chronic constipation: secondary analysis of a randomized controlled trial. CSBMs, EA, SCC
31  2023 Efficacy and safety comparison of PD-1 inhibitors vs. PD-L1 inhibitors in extensive-stage small-cell lung cancer: a retrospective comparative cohort study. CI, ES-SCLC, HR, ICIs, mOS, mPFS, OS, PD-1, PD-L1, PFS
32  2023 Efficacy and safety of 1.5% levofloxacin otic solution for the treatment of otitis media in a multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase III study. AOM, BICRC, CSOM, LVFX
33  2023 Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis. CIs, DCR, EGFR, HR, NMA, NSCLC, ORR, OS, PFS, PFS, RR
34  2023 Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis. BM, CR, CRS, MRD, OS, RFS
35  2023 Efficacy and safety of Ciprofol for procedural sedation and anesthesia in non-operating room settings. FB
36  2023 Efficacy and safety of ciprofol versus propofol for the induction of anesthesia in adult patients: a multicenter phase 2a clinical trial. MOAA/S
37  2023 Efficacy and Safety of COVID-19 Vaccination in Older Adults: A Systematic Review and Meta-Analysis. GMT, RCTs
38  2023 Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison. CG, CP, OS, PFS, TNBC
39  2023 Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial. BQT, H. pylori, HDDT, ITT, mITT, PP, PPI
40  2023 Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). AD, IL, LEB, PBO, TCS, TEAEs
41  2023 Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis. CI, CR, DCR, HCC, HR, OR, ORR, OS, PFS, PR
42  2023 Efficacy and safety of nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer. CCRT, CRR, LACC, ORR, OS, PFS
43  2023 Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention. DCR, MPM, ORR, PFS
44  2023 Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study. ARR, DMDs, EDSS, MS, RRMS, RTX
45  2023 Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis (RA): A Retrospective Study From Two Centers in Jeddah, Saudi Arabia. DAS, ESR, HDL, JAK, LDL, RA
46  2023 Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non-small Cell Lung Cancer Harboring Activating EGFR Mutations: A Systematic Review and Meta-analysis. EGFR, HR, ORR, OS, TKIs, VEGF
47  2023 Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study. IAC, OS, PFS, TIME, TLSs
48  2023 Endoscopic submucosal dissection using an ultrathin endoscope for superficial pharyngeal cancer: a prospective feasibility study (with video). ESD
49  2023 Endoscopic Ultrasound Guided Biliary Drainage in Malignant Distal Biliary Obstruction. EC-LAMS, EUS, EUS-BD, LAMS, MBO, PTBD, QoL
50  2023 Endoscopic ultrasound-guided gastroenterostomy for the management of gastric outlet obstruction: A large comparative study with long-term follow-up. ES, EUS-GE, GOO, LOS, surgical-GE
51  2023 Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration. DED, PK
52  2023 Exploring procedure duration and risk for serious adverse events during congenital cardiac catheterization. ---
53  2023 First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. DLT, MTD
54  2023 Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study. BCLC, CI, DCR, GSMs-TACE, HCC, IQR, ORR, OS, PFS
55  2023 Hiatal hernia repair with transoral incisionless fundoplication versus Nissen fundoplication for gastroesophageal reflux disease: A retrospective study. GERD, HH, LNF, TIF
56  2023 Hospitalisations Related to the Combination of ACE Inhibitors and/or Angiotensin Receptor Blockers with Diuretics and NSAIDs: A Post Hoc Analysis on the Risks Associated with Triple Whammy. ED, RORs
57  2023 Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system. FAERS
58  2023 Immunotherapy as a Promising Option for the Treatment of Advanced Chordoma: A Systemic Review. DLT, ICIs, OS, PFS, RECIST
59  2023 Incidence of adverse events for procedural sedation and analgesia for cardioversion using thiopental in elderly patients: a multicenter prospective observational study. JPSTAR, PSA
60  2023 Integrated safety and efficacy analysis of dasiglucagon for treatment of severe hypoglycaemia in individuals with type 1 diabetes. SH, T1D
61  2023 Integrative treatment program for the treatment of children with autism spectrum disorder: A prospective observational case series. ABC, ASD, CARS, HM, SET
62  2023 LIQUID - Treatment of high-grade dural arteriovenous fistulas with Squid liquid embolic agent: a prospective, observational multicenter study. DAVFs, mRS
63  2023 Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. cDAPSA, LDA, MDA/VLDA, PS, TNFi
64  2023 Long-term Evaluation of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients with Rheumatoid Arthritis Inadequately Responding to Biological Disease-modifying Antirheumatic Drugs. ACR, DMARDs, RA
65  2023 Long-term Safety and Efficacy of E6011, an Anti-fractalkine Monoclonal Antibody, in Patients with Rheumatoid Arthritis Inadequately Responding to Methotrexate. ACR, MTX, RA
66  2023 Longer versus shorter schedules of vincristine, irinotecan and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial. ORR12w, OS, PFS, VIT
67  2023 Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis. MDR-TB
68  2023 Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. IRs, UC
69  2023 Multicentre positive deviance to reduce adverse events and length of stay after pulmonary resection. LOS, PD
70  2023 Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data. DFS, ORR, pCR, TNBC
71  2023 Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: A systematic review and meta-analysis. IBS
72  2023 Novel Image-Guided Flexible-Probe Transbronchial Microwave Ablation for Stage 1 Lung Cancer. tMWA
73  2023 Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: a retrospective, single-center, three-arm study. DCR, ESCC, iPR, iSD, MPR, ORR, pCR, PFS
74  2023 Pharmacokinetic and bioequivalence of lenalidomide in multiple myeloma patients. AUC, CI, MM
75  2023 Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with breast, colorectal or gastric cancer under fed condition: A multicentric, randomized, open-label, single-dose, two-period, two-way crossover clinical trial. CIs, GMRs, SAEs
76  2023 Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. DLTs, NSCLC
77  2023 Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. CI, LSVT BIG, MD, NMAs, PD, PDQ-39, QoL, RCTs, RoB 2
78  2023 Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System. BCPNN, FAERS, IQR, MGPS, ROR, SOC
79  2023 Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study. DCR, HCC, HR, ICIs, mOS, mPFS, NLR, ORR, TACE, TKI, uHCC
80  2023 Prophylaxis of Neutropenia with Lipegfilgrastim in Breast Cancer Patients with Dose-Dense Chemotherapy: Results of a Noninterventional Study on Therapeutic Routine in Germany (NADENS). DD, IDD, NADENS, NIS
81  2023 Psychological Distress and Physical Adverse Events of COVID-19 Vaccination among Healthcare Workers in Taiwan. GEE, HCWs, NCKUH
82  2023 Reactogenicity and safety of second trimester maternal tetanus, diphtheria and acellular pertussis vaccination in the Netherlands. GA, Tdap
83  2023 Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data. OS, PFS, PR, RRMM
84  2023 Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan. ADRs, FVC, IPF
85  2023 Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study. HCC, TT
86  2023 Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea. ADRs, AS, CD, CDAI, IFX, KBASDAI, PMS, PsA, PsO, RA, SAEs, UC
87  2023 Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials. AITL, aNHL, CLL/SLL, CR, FL, iNHL, MCL, mPFS, ORR, OS, PDR, PR, RR, T-NHL
88  2023 Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials. RAASi
89  2023 Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial. IgG, NAb, pIMDs, RSV, SAEs
90  2023 Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study. atyMBCs, CoV-2 Nab, COVID-19, HC, MBC, MS, RBD
91  2023 Safety and performance of the Spectra Optia apheresis system for white blood cell depletion in patients with elevated white blood cell counts. WBC, WBCD
92  2023 Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer. 3wkCP, chemo-IO, DCR, ORR, OS, PFS, wkCP
93  2023 Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022. AESI, PTs, VAERS
94  2023 Safety of intrahospital transport for MR or CT scans in ventilated pediatric intensive care patients with congenital heart disease. CHD, MAP
95  2023 Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. mCRPC
96  2023 Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response. CR, CT, DWI, HCC, mRECIST, MRI, OS, PR, SD, TACE, TTP
97  2023 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults. AUC0-480h, C5a, COVID-19, IgG4, SAEs, TMDD
98  2023 Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience. CPs, PROs, SEs
99  2023 Stereotactic body radiation therapy (SBRT) as salvage treatment for early stage lung cancer with interstitial lung disease (ILD): An observational and exploratory case series of non-asian patients. ILD, LC, SBRT
100  2023 Stretching, Bracing, and Devices for the Treatment of Osteoarthritis-Associated Joint Contractures in Nonoperated Joints: A Systematic Review and Meta-Analysis. MD, OA, ROM